Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Parvus Asset Management is building a stake in Novo Nordisk and hopes to influence its choice of a new CEO. Novo Nordisk ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean. In ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight ...

STARING at yet another pregnancy test, Erica Coronado was thrilled but terrified. The 36-year-old had given up hope of a baby ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the ...